Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_assertion type Assertion NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_head.
- NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_assertion description "[In the attempt to find alternative therapeutic regimes for such patients, we tested PHA-848125, an oral pan cyclin-dependent kinase inhibitor currently under evaluation in phase II clinical trial, on a transgenic mouse model, K-Ras(G12D)LA2, which develops pulmonary cancerous lesions reminiscent of human lung adenocarcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_provenance.
- NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_assertion evidence source_evidence_literature NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_provenance.
- NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_assertion SIO_000772 20197397 NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_provenance.
- NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_assertion wasDerivedFrom befree-20140225 NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_provenance.
- NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_assertion wasGeneratedBy ECO_0000203 NP594876.RALFnfPQut1LJZKJEk6A1nIQc8tja9WyfqLiLugCmv4Ys130_provenance.